1.study of side effect of glucocorticoid in asthma patients at Allergic - MDLS Department of Bach mai hospital
Journal of Practical Medicine 2005;503(2):2-4
Retrospective study on 1026 patients with asthma at Bach Mai Hospital from 1 January 1998 to 31 January 2002. Among them, 69.4% were 21 to 50 years old, with no different in sex. Hospitalized rate was highest in annual November. Glucocorticoid was used in all these patients with common kinds as solu-medrol: 76.2%; prednisolone: 67.7%; depersolone: 44.3% và Pulmicort: 7.6%. Rate of complication related to glucocorticoids was 28.7%. There were 24 types of symptom, including high blood glucose (11.5%), hypokaliemia (9.45%), hypertension (3.45%), gastric ulcer (2.83%), Cushing syndrome (2.53%). 7 systems damaged were endocrine (27.54%), musculoskeletal (4.28%), skin and mucous membrane (3.19%), gastrointestinal (4.96%), cardiovascular (3.7%), nervous and sense organs. There were 10 kinds of diseases and syndroms related to glucocorticoid use: hypertension, gastric ulcer, Cushing syndrome, diabetes, ponosis, retarded development, urticaria, anapphylactic shock, cataract, metal disorders, secondary bacterial contamination
Asthma
;
Glucocorticoids/adverse effects
;
Pharmaceutical Preparations
2.Research progress on desensitization of hypersensitivity reaction to iodinated contrast media.
Miao FAN ; Xiaomeng ZHENG ; Suyan ZHU
Journal of Zhejiang University. Medical sciences 2023;52(4):526-530
Desensitization therapy for iodinated contrast media (ICM) aims to induce drug tolerance in patients with a history of severe allergic reactions to ICM in a short time. Currently, there is no widely accepted consensus on inducing desensitization to avoid severe allergic responses to ICM. The clinically successful cases have shown that prophylactic use of antihistamines and glucocorticoids can increase the desensitization effect; repeatedly desensitizing and gradually increasing the dose can be conducive to establishing better tolerance to ICM. Most desensitization effects, including stress resistance, can endure 24-48 h. The mechanisms of desensitization therapy remain unclear, the initial dose, administration interval and dose gradient are largely based on clinical experiences and the reaction of patients. This article reviews the current research progress on ICM-related allergies, desensitization methods and related mechanisms, as well as the benefits and hazards of desensitization, to provide a reference for desensitization treatment of hypersensitivity to ICM .
Humans
;
Contrast Media/adverse effects*
;
Consensus
;
Glucocorticoids
;
Hypersensitivity
3.Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: a retrospective analysis.
Rui-Yan WANG ; Hui CHEN ; Zhi-Xin HUANG ; Yong CHEN ; Jian-Min ZHONG
Chinese Journal of Contemporary Pediatrics 2023;25(10):1034-1039
OBJECTIVES:
To investigate the clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis (OMG).
METHODS:
A retrospective analysis was conducted on 130 children with OMG who were treated in the Department of Neurology, Jiangxi Children's Hospital, from February 2018 to February 2023. According to the treatment regimen, they were divided into four groups: glucocorticoid (GC) group (n=29), mycophenolate mofetil (MMF) group (GC+MMF; n=33), methotrexate (MTX) group (GC+MTX; n=30), and tacrolimus (FK506) group (GC+FK506; n=38). Treatment outcomes and adverse reactions were compared among the groups.
RESULTS:
After 3 months of treatment, the FK506 group had significantly lower scores of Myasthenia Gravis Quantitative Scale and Myasthenia Gravis-Specific Activities of Daily Living than the other three groups (P<0.05). After 3 months of treatment, the FK506 group had a significantly lower dose of prednisone than the GC group, and after 6 and 9 months of treatment, the MMF, MTX, and FK506 groups had a significantly lower dose of prednisone than the GC group (P<0.05). After 12 months of treatment, the MMF, MTX, and FK506 groups had a significantly lower incidence rate of GC-related adverse reactions than the GC group (P<0.05).
CONCLUSIONS
For children with OMG, the addition of various immunosuppressants can reduce the dosage of GC and adverse reactions. Among them, FK506 shows superior efficacy compared to other immunosuppressants in the early treatment of OMG.
Humans
;
Child
;
Prednisone/adverse effects*
;
Tacrolimus/adverse effects*
;
Retrospective Studies
;
Activities of Daily Living
;
Immunosuppressive Agents/adverse effects*
;
Myasthenia Gravis/drug therapy*
;
Glucocorticoids/therapeutic use*
;
Mycophenolic Acid/adverse effects*
4.Pathogenesis of glucocorticoid-induced osteoporosis based on label-free mass proteomics.
Fang-Qing ZHANG ; Qiu-Yue LI ; Yue SHI ; Jing-Xun WANG ; Jia-Shuo WU ; Hao-Nan RUAN ; Hao-Tian XUE
China Journal of Orthopaedics and Traumatology 2023;36(4):336-344
OBJECTIVE:
To explore pathogenesis of glucocortocoid-induced osteoporosis(GIOP) based on label-free mass proteomics.
METHODS:
Twevle female Sprague-Dawley(SD) rats were randomly divided into two groups, named as sham group and GIOP group. After one-week adaptive feeding, the rats of GIOP group were administered with dexamethasone via intramuscular injection according to 2.5 mg/kg weighting, while the rats of sham group were administered with the same amount of saline, twice a week. The tibias of each group were collected after 8-week modeling and made pathological sections to confirm the success of modeling. Three samples of each group were picked up to perform label-free mass proteomics. After quality control, differentially expressed proteins were identified according to qualitative and quantitative analyses. Then gene ontology(GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis, cluster analysis as well as protein-protein interaction analysis were performed using bioinformatics analysis.
RESULTS:
Compared with sham group, the structure of bone trabecular in GIOP group showed abnormal arrangement, uneven distribution and obvious fragmentation, which could demonstrate successful modeling. A total of 47 differentially expressed proteins (DEPs) were identified including 20 up-regulated and 27 down-regulated proteins. The expression of protein nucleophosmin 1(NPM1), adipocyte plasma membrane associated protein (APMAP), cytochromec oxidase subunit 6A1 (COX6A1) and tartrate-resistant acid phosphatase (ACP5) showed a significant difference between two groups. KEGG results showed DEPs were enriched on metabolism-related pathways, immune-related pathways and AMP-activated kinase (AMPK) signaling pathway.
CONCLUSION
Protein NPM1, APMAP, COX6A1 and ACP5 showed a close relationship with pathogenesis of GIOP, which could serve as potential biomarkers of GIOP. AMPK signaling pathway played an important role in the occurrence and development of GIOP, which could be regarded as potential signaling pathway to treatment GIOP.
Female
;
Rats
;
Animals
;
Glucocorticoids/adverse effects*
;
AMP-Activated Protein Kinases
;
Proteomics
;
Rats, Sprague-Dawley
;
Osteoporosis/genetics*
;
Nuclear Proteins/adverse effects*
5.Efficacy and safety of low-dose rituximab in treatment of pediatric nephrotic syndrome: a prospective randomized controlled trial.
Ying ZHU ; Ling WU ; Yun WANG ; Ya-Feng ZHU ; Yin PENG ; Shao-Han FANG ; Luo-Dan ZHANG ; Fang DENG
Chinese Journal of Contemporary Pediatrics 2023;25(6):606-611
OBJECTIVES:
To study the efficacy and safety of repeated application of rituximab (RTX) at a low dose (200 mg/m2) versus the recommended dose (375 mg/m2) for remission maintenance in frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
METHODS:
A randomized controlled trial was conducted for 29 children with FRNS/SDNS who received systemic treatment in the Department of Nephrology, Anhui Provincial Children's Hospital, from September 2020 to December 2021. These children were divided into a recommended dose group (n=14) and a low dose group (n=15) using a random number table. The two groups were compared in terms of general characteristics, changes in CD19 expression after RTX treatment, number of relapses, glucocorticoid dose, adverse reactions of RTX, and hospital costs.
RESULTS:
After RTX treatment, both the low dose group and the recommended dose group achieved B-lymphocyte depletion and had significant reductions in the number of relapses and glucocorticoid dose (P<0.05). The low dose group had a comparable clinical effect to the recommended dose group after RTX treatment (P>0.05), and the low dose group had a significant reduction in hospital costs for the second, third, and fourth times of hospitalization (P<0.05). There were no serious adverse reactions in either group during RTX treatment and late follow-up, and there was no significant difference in adverse reactions between the two groups (P>0.05).
CONCLUSIONS
Repeated RTX treatment at a low dose has comparable clinical efficacy and safety to that at the recommended dose and can significantly reduce the number of FRNS/SDNS relapses and the amount of glucocorticoids used, with little adverse effect throughout the treatment cycle. Therefore, it holds promise for clinical application.
Humans
;
Child
;
Nephrotic Syndrome/drug therapy*
;
Rituximab/adverse effects*
;
Glucocorticoids/adverse effects*
;
Prospective Studies
;
Adaptor Proteins, Signal Transducing
6.Clinical application and side effects of immunosuppressant.
Chinese Journal of Contemporary Pediatrics 2007;9(2):107-112
Adjuvants, Immunologic
;
adverse effects
;
therapeutic use
;
Azathioprine
;
adverse effects
;
therapeutic use
;
Cyclosporine
;
adverse effects
;
therapeutic use
;
Glucocorticoids
;
adverse effects
;
therapeutic use
;
Humans
;
Mycophenolic Acid
;
adverse effects
;
analogs & derivatives
;
therapeutic use
;
Tacrolimus
;
adverse effects
;
therapeutic use
7.Patient with pemphigus vulgaris complicated with dysfunctional uterine bleeding upon glucocorticoid usage: a case report.
Hui FENG ; Xiaobo LUO ; Jiang LU ; Qianming CHEN
West China Journal of Stomatology 2015;33(2):218-220
Pemphigus is a severe chronic autoimmune mucocutaneous bullous disease. Glucocorticoids are considered as the first line of treatment for this disease. Dysfunctional uterine bleeding is also observed as a result of hypothalamic-pituitary-ovary axis dysfunction. This study reported one female patient with pemphigus vulgaris complicated with dysfunctional uterine bleeding upon systemic glucocorticoid usage. Before this disease was diagnosed, the patient experienced normal menstruation. The mechanism of dysfunctional uterine bleeding triggered by glucocorticoids is elucidated on the basis of case studies and literature review.
Female
;
Glucocorticoids
;
adverse effects
;
Humans
;
Metrorrhagia
;
chemically induced
;
Pemphigus
;
drug therapy
8.Investigation on the role on perindopril for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits.
Feng ZHOU ; Chun RONG ; Kai WANG ; Chun-sheng WANG ; Yong-tao ZHANG
China Journal of Orthopaedics and Traumatology 2016;29(1):52-57
OBJECTIVETo investigate the role of perindopril for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) in rabbits.
METHODSA total of 45 male New Zealand white rabbits (10 months old, weight 3.0 to 3.5 kg) were randomly divided into 3 groups involving normal control group (muscle injection of saline solution, n = 15, group NC), model group (muscle injection of dexamethasone, n = 15, group GIOP), and treatment group (muscle injection of dexamethasone combined with oral perindopril, n = 15, group GIOP+ACEI). All rabbits put to death after 12 weeks' treatment. The changes of bone mass and strength were observed and analyzed by bone histomorphology, biomechanics, metabolic bone related serological indexes and mRNA expression.
RESULTSAt 12 weeks, the analysis of bone histomorphology and biomechanics results showed that the bone mass and bone strength of group GIOP were significantly lower than that of group NC (P < 0.05); after perindopril treatment, the bone mass and bone strength of group GIOP+ACEI were higher obviously than that of group GIOP (P < 0.05). Mineralizing surface,mineral apposition rate and serum osteocalcin in group GIOP decreased than group NC; however, osteoclast number, osteoclast surface, eroded surface, and urinary deoxypyridinoline in group GIOP increased than group NC (P < 0.05); these changes were inhibited after perindopril treatment (P < 0.05). Quantitative RT-PCR revealed that after dexamethasone treatment, the ratio of SOST mRNS expression and RANKL/OPG mRNA expression obviously increased than that of group NC (P < 0.05); and Runx2 expression decreased significantly (P < 0.05); while the changes of mRNA expression were improved by perindopril treatment.
CONCLUSIONPerindopril can promote bone formation and inhibit bone resorption to deduce glucocorticoid-induced osteoporosis. This study provides a new method for prevention and treatment of GIOP.
Animals ; Biomechanical Phenomena ; Glucocorticoids ; adverse effects ; Male ; Osteoporosis ; chemically induced ; prevention & control ; Perindopril ; therapeutic use ; Rabbits